Answers are grounded in this paper and cite their sources.
Prospective multicenter trial evaluates nivolumab plus ipilimumab in advanced gallbladder cancer, highlighting dual checkpoint inhibition as an alternative to chemotherapy.
Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open-label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: